Please wait…

Login required

Username or email:

To use this function please log-in
If you haven't got an account on, you have the opportunity to register regist here for free.

add instrument

Pictet - Biotech-P USD

Pictet - Biotech-P USD

ISIN LU0090689299 | WKN 988562 | Mnemonic PBF | Type fund
21/05/2019 15:32
Bid Ask
This product is subject to quotation restrictions.
Change from Prev. Day 0.00 EUR / 0.00%
Spread absolute / relative 9,13 / 1,49%

Net Asset Value

Previous Day 687.90 USD Date 20/05/2019

Price Information

Last Price 603.6900
Date / Time 21.05.2019 / 15:32:48
Price -
Volume in euro -
Volume Size -
High 0.000
Low 0.000
52 week High 670.060
52 week Low 509.790
Trading Hours 09:00 - 18:00

Price History

Date Opening Price Closing Price Daily High Daily Low Volume (pcs.)
21/05/2019 603.6000 603.6900 603.6900 600.4700
20/05/2019 610.4500 610.4500 610.4500 610.4500
17/05/2019 618.8100 613.2400 618.8100 613.2400
16/05/2019 599.3900 599.6600 599.6600 599.3900
15/05/2019 593.1100 600.1100 600.1100 593.1100


Management Fee 1.60 %
Custodian Fee 0.02 %
Capital forming savings possible? yes
Savings Plan yes
Distribution Non Distributing

Frankfurt Trading Parameters

Continous Quotation no
Minimum tradeable Unit 1

Rating for Pictet - Biotech-P USD

€uro FondsNote 4
Lipper Leaders, 3 years
Lipper Leaders, 5 years
Lipper Leaders, 10 years
Lipper Leaders, overall


Fundamental Data

WKN 988562
ISIN LU0090689299
Name Pictet - Biotech-P USD
Investment Company Pictet
Issued in Luxemburg
Issue Date 30/11/1995
Category Aktienfonds Biotechnologie
currency USD
Volume 505,451,192.96
Depositary Bank Pictet & Cie (Europe) S.A.
Paying Agent Deutsche Bank
Fund Management Nathalie Flury, Tazio Storni
Fiscal Year-End 30.09.
Last Update 07/06/2016

Investment policy

invest like Pictet - Biotech-P USD: Der Fondsmanager legt mindestens zwei Drittel des Fondsvermögens in Aktien oder ähnlichen Titeln von besonders innovativen Unternehmen für medizinische Biotechnologieanwendungen an. Als Finanzinstrumente kommen hauptsächlich international börsennotierte Wertpapiere in Frage. Angesichts des besonders innovativen Charakters der Pharmaindustrie in Nordamerika und Westeuropa erfolgt jedoch das klare Hauptengagement in diesen geografischen Gebieten. Der Fondsmanager kann in chinesische A-Aktien investieren über (i) die einer Gesellschaft der Pictet Gruppe gewährte QFII-Quote (bis zu maximal 35% seines Nettovermögens), (ii) die einer Gesellschaft der Pictet Gruppe gewährte RQFII-Quote und/oder (iii) das Shanghai-Hong Kong Stock Connect Programm. Der Fondsmanager kann auch derivative Finanzinstrumente zu chinesischen A-Aktien einsetzen.

The following Disclaimer and Information has been prepared by Voltabox AG (the “Issuer”) for the purpose of publishing THE securities prospectus by the issuer. Deutsche Boerse AG does not assume any responsibility for the content of the issuer`s Disclaimer and information.


Important Information


The information contained on the following web pages is directed only at persons who are resident of or domiciled in the Federal Republic of Germany (“Germany”) or the Grand Duchy of Luxembourg (“Luxembourg”). The following information does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for any securities. No offer of securities of the Issuer is being, or will be, made to the public outside Germany and Luxembourg. The offer in Germany and Luxembourg is being made solely on the basis of the securities prospectus (including any amendments thereto) which has been approved by the German Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin) and which has been published on the Issuer’s website. Any investment decision regarding the publicly offered securities of the Issuer should only be made on the basis of the securities prospectus. The securities prospectus is available free of charge from the Issuer (Artegastraße 1, 33129 Delbrück, Germany; Tel.: +49 (0)5250 9930-900; Fax: +49 (0)5250 9762-102) and on the Issuer’s website (

The information contained on the following web pages is not an offer of securities for sale or a solicitation of an offer to purchase securities in the United States of America (“United States”), Canada, Australia or Japan. The Issuer’s shares, and the securities offered in the course of the offer, have not been and will not be registered under the US Securities Act of 1933, as amended (“Securities Act”), or with any other securities regulatory authority of any state or other jurisdiction of the United States and may not be offered, sold or delivered within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. The Issuer does not intend to register the offer or parts thereof in the United States or make an offer to the public in the United States, Canada, Australia or Japan.

The information contained on the following web pages is not for distribution to persons who are located in the United States, Canada, Australia or Japan or any other jurisdiction where the offer of the securities to the public is not taking place. Any violation of these restrictions may constitute a breach of the securities laws of these countries. The copying, forwarding or other transmission of the content of the following web pages is prohibited.

By clicking the "I AGREE" button below, you warrant that (i) you have read and accepted the foregoing information and restrictions in full and (ii) you are a resident of or domiciled in Germany or Luxembourg, and (iii) you agree not to distribute or forward the information contained on the following web pages to any person who is not a resident of or domiciled in Germany or Luxembourg.


We regret that, due to regulatory restrictions, we are unable to provide you with access to the following web pages.